MAICs demonstrate improved clinical benefit of TALA+ENZA in metastatic castration-resistant prostate cancer, suggesting it as a viable treatment option.
MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: